EP0511300A4 - Monoclonal antibody specific for non-immunodominant epitope of hiv proteins - Google Patents

Monoclonal antibody specific for non-immunodominant epitope of hiv proteins

Info

Publication number
EP0511300A4
EP0511300A4 EP19910903736 EP91903736A EP0511300A4 EP 0511300 A4 EP0511300 A4 EP 0511300A4 EP 19910903736 EP19910903736 EP 19910903736 EP 91903736 A EP91903736 A EP 91903736A EP 0511300 A4 EP0511300 A4 EP 0511300A4
Authority
EP
European Patent Office
Prior art keywords
monoclonal antibody
antibody specific
immunodominant epitope
hiv proteins
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19910903736
Other languages
English (en)
Other versions
EP0511300A1 (fr
Inventor
Paul J. Higgins
Charles F. Scott, Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
REPLGIEN Corp
Original Assignee
REPLGIEN Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by REPLGIEN Corp filed Critical REPLGIEN Corp
Publication of EP0511300A1 publication Critical patent/EP0511300A1/fr
Publication of EP0511300A4 publication Critical patent/EP0511300A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP19910903736 1990-01-16 1991-01-16 Monoclonal antibody specific for non-immunodominant epitope of hiv proteins Withdrawn EP0511300A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46503590A 1990-01-16 1990-01-16
US465035 1990-01-16

Publications (2)

Publication Number Publication Date
EP0511300A1 EP0511300A1 (fr) 1992-11-04
EP0511300A4 true EP0511300A4 (en) 1993-05-26

Family

ID=23846250

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19910903736 Withdrawn EP0511300A4 (en) 1990-01-16 1991-01-16 Monoclonal antibody specific for non-immunodominant epitope of hiv proteins

Country Status (4)

Country Link
EP (1) EP0511300A4 (fr)
JP (1) JPH05506142A (fr)
CA (1) CA2073060A1 (fr)
WO (1) WO1991010742A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT66445A (en) * 1990-10-26 1994-11-28 New York Health Res Inst Monoclonal antibodies specific for the v3 loop and cd-4 binding site of hiv-1 gp120
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
DE19809785C2 (de) * 1998-03-08 2000-02-10 Wolfgang Bergter Radioimmunpharmakon zur Behandlung der HIV-1-Infektion
US8481041B2 (en) 2005-04-06 2013-07-09 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy
WO2007084692A2 (fr) * 2006-01-20 2007-07-26 Welson Pharmaceuticals, Inc. Immunoconjugués pour le traitement de maladies infectieuses
CN101506358B (zh) * 2006-05-15 2013-07-17 免疫医学股份有限公司 使用偶合的抗体或抗体片段治疗人免疫缺陷病毒感染的方法和组合物
CN107614515B (zh) 2015-05-28 2022-03-22 免疫医疗公司 用于抗hiv(人免疫缺陷病毒)疗法和/或疫苗的t20构建体
WO2017093985A1 (fr) 2015-12-05 2017-06-08 Centre Hospitalier Universitaire Vaudois Agents de liaison au vih

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988005824A1 (fr) * 1987-02-02 1988-08-11 E.I. Du Pont De Nemours And Company Selection d'anticorps monoclonaux contre des glycoproteines virales
US4861707A (en) * 1987-02-02 1989-08-29 E. I. Du Pont De Nemours And Company Human immunodeficiency virus antigen

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2437213A1 (fr) * 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988005824A1 (fr) * 1987-02-02 1988-08-11 E.I. Du Pont De Nemours And Company Selection d'anticorps monoclonaux contre des glycoproteines virales
US4861707A (en) * 1987-02-02 1989-08-29 E. I. Du Pont De Nemours And Company Human immunodeficiency virus antigen

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Cell, Volume 46, issued 1986, J.M. COFFIN, "Genetic Variation in AIDS viruses", pages 1-4, see paragraph bridging pages 1 and page 2, and page 3. *
IMMUNOLOGY vol. 68, 1989, OXFORD,U.K. pages 325 - 331 OHLIN ET AL 'HUMAN MONOCLONAL ANTIBODIES AGAINST A RECOMBINANT HIV ENVELOPE ANTIGEN PRODUCED BY PRIMARY IN VITRO IMMUNIZATION.CHARACTERIZATION AND EPITOPE MAPPING' *
See also references of WO9110742A1 *

Also Published As

Publication number Publication date
CA2073060A1 (fr) 1991-07-17
EP0511300A1 (fr) 1992-11-04
WO1991010742A1 (fr) 1991-07-25
JPH05506142A (ja) 1993-09-16

Similar Documents

Publication Publication Date Title
NZ236000A (en) Oligomeric monoclonal igg antibody composition
HU896763D0 (en) Process for the preparation of bispecific monoclonal antibody
AU5525090A (en) Monoclonal antibody to amyloid peptide
GB8719587D0 (en) Monoclonal antibodies & peptides
GB9112836D0 (en) Production of monoclonal antibodies
GB8608068D0 (en) Monoclonal antibodies
IL90017A0 (en) Monoclonal antibodies
GB8910263D0 (en) Monoclonal antibodies specific for an immunoglobulin isotype
GB2158094B (en) Anti-human igg monoclonal antibody and process for preparing the same
ZA898777B (en) Monoclonal antibodies
EP0511300A4 (en) Monoclonal antibody specific for non-immunodominant epitope of hiv proteins
AU7068587A (en) Monoclonal antibody immunoblot assay for antigens
GB2254326B (en) Monoclonal antibodies produced by in vitro immunization of lymphocytes
IL92232A0 (en) Anti-fucosylceramide monoclonal antibody
EP0267601A3 (en) Anti-pci monoclonal antibody
HU895916D0 (en) Process for the preparation of monoclonal antibody recognaizing reg protein
GB8927389D0 (en) Monoclonal antibodies
GB8820036D0 (en) Monoclonal antibodies
GB8610202D0 (en) Monoclonal antibodies
GB8610203D0 (en) Monoclonal antibodies
EP0348973A3 (en) Anti-human pulmonary adenocarcinome monoclonal antibody
EP0336441A3 (en) Anti-cpbii monoclonal antibody
ZA912136B (en) Anti-oncostatin m monoclonal antibodies
GB8619905D0 (en) Monoclonal antibody
IE901210L (en) Monoclonal antibody

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19920717

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19930406

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

16A New documents despatched to applicant after publication of the search report
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19950201